Cerba Research Announces Time-Saving COVID-19 Exploratory Tools and NGS Advancements

GHENT, Belgium–(BUSINESS WIRE)–Cerba Research broadcasts in the present day that it has developed two new COVID-19 exploratory instruments to boost medical analysis for the event of vaccines and coverings for COVID-19 and different infectious illnesses. Developed by scientists at Cerba Healthcare on nasopharyngeal ongoing affected person samples, these instruments can be found and environment friendly on medical specimens. Moreover, this whole-genome sequencing in NGS assay is offered for different viruses answerable for respiratory illnesses like influenza viruses.

The developments reinforce Cerba Healthcare and Cerba Analysis’s scientific dedication to the continued battle in opposition to the pandemic. Cerba Analysis not too long ago announced its In Vitro Diagnostic (IVD) division supported The French Public Well being Company (Santé Publique France) in a potential COVID-19 seroprevalence examine now recognized as a significant accomplice for epidemiological research with the French Authorities.

“Because the onset of the pandemic, Cerba Healthcare has been on the forefront of combating in opposition to COVID-19 with all stakeholders, together with sufferers, healthcare professionals, governments, IVD professionals, and pharmaceutical and biotechnology corporations growing vaccines and coverings. Our new COVID-19 exploratory instruments assist our medical analysis clients develop extra tailor-made and efficient therapies,” mentioned Jérôme Sallette, chief scientific officer at Cerba Analysis.

Additional data:

Viral load measurement for SARS-CoV-2 utilizing digital droplet PCR

• Use in therapy and vaccine trials
• An progressive technique enabling SARS CoV-2 absolute quantification
• Elevated sensitivity and precision as in comparison with qPCR assays, particularly in low viral abundance samples
• Comply with-up of sufferers with low viral load
• Correct evaluation in viral load variation
• Carried out in an ISO15189 accredited lab

Entire-genome sequencing in NGS of the SARS-CoV-2 and different respiratory viruses

• Use in therapy and vaccine trials
• Viral dedication and subtyping (SARS CoV-2, influenza, RSV, adenovirus, pneumovirus, rhinovirus)
• Detection of virus mutations
• Evaluation of viral heterogeneity and quasispecies
• Exact detection of co-infections (e.g., influenza subtype)
• Documentation of confirmed reinfections
• May be mixed to host genetics to handle particular person genetic susceptibility to an infection, degree of the immune response, or severity prognosis elements

About Cerba Analysis

Cerba Research is a number one healthcare diagnostic firm with end-to-end drug growth and diagnostic options to optimize R&D drug productiveness and commercialization. Offering world medical trial central laboratory options (speciality lab, FCM, ICH, NGS, BioA, metabolomics), translational science (biomarkers growth, CDx, biobanking), and IVD (biospecimens, potential and retrospective pattern assortment, IVD analysis).

About Cerba Healthcare

Cerba Healthcare, the mother or father firm of Cerba Analysis, is a world community of medical biology laboratories that provides a whole resolution when it comes to organic diagnostics, starting from the gathering centre to the speciality laboratory.